AM095 and AM966, two potent LPA1 antagonists, have demonstrated efficacy in reducing tissue injury, inflammation, and fibrosis in IPF mouse models [12, 13]. The gene discussed is LPAR1; the disease is idiopathic pulmonary fibrosis.